Our patients have spoken: “We want earlier diagnoses to stop disease progression and better biomarkers for earlier diagnosis”
On March 8th, 2017, the Arthritis Foundation, US Food and Drug Administration (FDA), osteoarthritis (OA) patients, drug developers, health care providers and academic researchers came together to discuss the serious burden of OA disease, particularly the most significant OA-related symptoms, the impact of those symptoms, currently available treatments and ideal treatments.
Continue reading Summary & Results from Osteoarthritis Patient-Focused Drug Development Meeting
Close to 200 patients, FDA staff, industry leaders, members of the media and academic personnel listened or participated in the groundbreaking Osteoarthritis Patient-Focused Drug Development meeting on March 8. The meeting was a forum for OA patients to share their experiences with the disease and talk about the signs and symptoms that matter most to them.
Continue reading Highlights from 2017 Osteoarthritis Patient-Focused Drug Development Meeting
Last year, the Arthritis Foundation cosponsored the Accelerating Osteoarthritis (OA) Clinical Trials Workshop with the US Food and Drug Administration (FDA). The focus of the workshop aimed at identifying ways to get new diagnostics & treatments to clinics faster for the arthritis community. Important key takeaways from the workshop included a focus on patients – how they need to be more involved in the scientific discovery process and that scientists should consider their needs and wants in designing clinical trials.
Continue reading Arthritis Foundation to Host Meeting for Osteoarthritis Patients to Share their Stories with the FDA